Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Novartis None |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00171886 |
Primary Acromegaly is a clinical and metabolic disease caused by growth hormone (GH) hypersecretion from a pituitary adenoma and is an insidious, chronic disease that is associated with bony and soft tissue overgrowth. Goals of therapy are to eradicate the tumor, suppress GH secretion, normalize IGF-I levels, and preserve normal pituitary function.
This study will evaluate the safety and efficacy of octreotide as primary therapy for the treatment of acromegaly and as therapy for patients with acromegaly and a pituitary macroadenoma or microadenoma.
Condition | Intervention | Phase |
---|---|---|
Acromegaly |
Drug: Octreotide |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Octreotide Efficacy and Safety in First-Line Acromegalic Patients |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Other protocol-defined inclusion / exclusion criteria may apply.
Study ID Numbers: | CSMS995BES02 |
Study First Received: | September 13, 2005 |
Last Updated: | August 17, 2006 |
ClinicalTrials.gov Identifier: | NCT00171886 |
Health Authority: | Spain: Spanish Agency of Medicines |
Acromegaly Otreotide Tumor reduction |
Bone Diseases, Endocrine Hypothalamic Diseases Pituitary Diseases Musculoskeletal Diseases Octreotide Endocrine System Diseases |
Central Nervous System Diseases Endocrinopathy Brain Diseases Bone Diseases Acromegaly |
Hyperpituitarism Antineoplastic Agents, Hormonal Antineoplastic Agents Therapeutic Uses |
Nervous System Diseases Gastrointestinal Agents Pharmacologic Actions |